Skip to main content
Company profile
Annexon, Inc. logo

Annexon, Inc.

Pipeline5 assets

  • TanruprubartANX005 / C1q / classical complement pathway / IV mAb / Autoimmune / neurology
    Guillain-Barré SyndromeMAA filed; FDA discussions ongoingactiveUSEU
  • VonaprumentANX007 / C1q / classical complement pathway / IVT Fab / Ophthalmology
    Geographic AtrophyPhase 3ARCHER II enrollment completed; data expected 2H26
  • ANX1502ANX1502 / Classical complement pathway / Oral small molecule / Autoimmune
    Cold Agglutinin DiseaseProof-of-conceptactive; update upon CAD study completion in 2026
  • ANX005ANX005 / C1q / classical complement pathway / IV mAb / Neurodegeneration
    Huntington’s DiseasePoised for late-stage Phase 2b/3activeAmyotrophic Lateral SclerosisPoised for late-stage Phase 2b/3active
  • ANX009ANX009 / C1q / classical complement pathway / Subcutaneous Fab / Autoimmune
    Lupus NephritisEvaluating options for future development

Latest news16 items

All news

Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study

BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced the addition of a

Trial Design Update • Phase 3

Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week

Early Outcomes Reinforce the Consistency and Reproducibility of Tanruprubart Treatment Effect Previously Demonstrated in Phase 3 and Real-World Evidence Studies Potential to Become the First Approved Targeted Therapy to Treat GBS Worldwide, Addressing the Significant Unmet Need and Over $20

Interim DataInterim data Thu, Aug 6, 2026

Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026

BRISBANE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced an oral presentation

Presentation / Abstract • Phase 2ASRS oral presentation Sat, Jul 18, 2026, 10:44 AM EDT

Annexon to Participate in Upcoming June Investor Conferences

BRISBANE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love,

Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference

BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love,